Skip to main content

Dhingra Ankur's Form 4/A amendment

Amended

Summit Therapeutics Inc. (SMMT) · filed Mar 8, 2023

Accession no.
0001849682-23-000002
Filed
Mar 8, 2023
Trade date
Aug 16, 2022
Filing delay
204 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Aug 17, 2022

This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $36.6K. It was filed 204 days after the trade.

This amendment replaces 0001599298-22-000102 (filed Aug 17, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dhingra AnkurCIK 0001849682Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2022Common StockPPurchaseAcquired+13,027$0.97+$12,636.1939,527Direct
Aug 16, 2022Common StockPPurchaseAcquired+24,658$0.97+$23,918.2638,196Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)